3,147 reports of this reaction
2.5% of all SODIUM OXYBATE reports
#8 most reported adverse reaction
DEPRESSION is the #8 most commonly reported adverse reaction for SODIUM OXYBATE, manufactured by Jazz Pharmaceuticals, Inc.. There are 3,147 FDA adverse event reports linking SODIUM OXYBATE to DEPRESSION. This represents approximately 2.5% of all 126,117 adverse event reports for this drug.
SODIUM OXYBATE has an overall safety score of 85 out of 100. Patients taking SODIUM OXYBATE who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is a less commonly reported adverse event for SODIUM OXYBATE, but still significant enough to appear in the safety profile.
In addition to depression, the following adverse reactions have been reported for SODIUM OXYBATE:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 3,147 FDA reports for SODIUM OXYBATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 2.5% of all adverse event reports for SODIUM OXYBATE, making it a notable side effect.
If you experience depression while taking SODIUM OXYBATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.